GAITHERSBURG, Md., Feb. 22,
2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq:
YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and
delivering new generations of vaccines and therapeutic biologics
for infectious diseases and cancer, today announced the results of
its extraordinary general meeting (the "EGM") held on February 22, 2024 in Hong Kong. The Company's shareholders voted in
favor of each of the following resolutions:
Resolution 1 : as an ordinary resolution, that the appointment
of each of Haitao Zhao, Henry Chen, Pierson Yue
Pan, Yuntao Cui, Jin Wang, Chunyuan
(Brenda) Wu as a director of the Company is hereby
reaffirmed, ratified and confirmed in all respects.
Resolution 2 : as an ordinary resolution, that the Company is
hereby authorized and directed to conduct an independent
investigation of any alleged misconduct and/or illegal
activities of the Company caused by or under the control of Mr.
Yi Zhang, the former chairperson of
the Company's Board of Directors.
Resolution 3 : as an ordinary resolution, that the Company is
hereby authorized and directed to take immediate actions to
strengthen the Company's corporate governance and internal control
and management as advised by counsel and other professionals.
Resolution 4 : as an ordinary resolution, that the Company is
hereby authorized and directed to remove Mr. Yi Zhang from all positions with the Company and
any subsidiaries of the Company, including without limitation as
director, officer and/or legal representative.
As of 5:00 p.m. on the EGM's
record date of February 16, 2024
(Hong Kong time), the Company had
188,327,959 ordinary shares issued and outstanding. Members holding
107,110,641 ordinary shares cast their votes at the EGM. The
results of the vote on each of the resolutions submitted for
shareholder approval at the EGM were 99,472,858 votes in favor and
6,508,744 votes against and 1,129,039 votes abstained.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and commercializing new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer. It has developed a proprietary PIKA®
immunomodulating technology platform and a series of preventive and
therapeutic biologics with a potential for improved Rabies,
Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS
Biopharma operates in China,
the United States, Singapore and the
Philippines, and is led by a management team that combines
rich local expertise and global experience in the
bio-pharmaceutical industry. For more information, please visit
investor.ysbiopharm.com.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-results-of-extraordinary-general-meeting-held-on-february-22-2024-302069235.html
SOURCE YS Biopharma Co., Ltd.